Drug Profile


Alternative Names: Alvesco; Alvesco HFA; BTR-15; BTR-15K; BY 9010; Ciclesonide DPI; Ciclesonide I.S.; Ciclesonide pMDI; EL 876; Omnair; Omnaris; Omnaris HFA; RPR 251526; TBN-15; XRP 1526; Zetonna

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nycomed
  • Developer Sunovion Pharmaceuticals; Takeda; Takeda Pharmaceuticals International GmbH; Teijin Pharma
  • Class Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 13 Jul 2017 Covis Pharma acquires US market rights of ciclesonide from Sunovion Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Perennial-allergic-rhinitis in United Kingdom (Intranasal, Aerosol)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in United Kingdom (Intranasal, Aerosol)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top